Follow-up Issues for Early Stage Breast Cancer: The Role of Surveillance and Long-Term Care
|
|
- Barnaby Beasley
- 5 years ago
- Views:
Transcription
1 Follow-up Issues for Early Stage Breast Cancer: The Role of Surveillance and Long-Term Care Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California San Francisco Comprehensive Cancer Center
2 A Growing and Important Issue >200,000 new cases of invasive breast cancer per year in U.S. Additional >50,000 cases of DCIS The majority of patients will have early stage disease Treatment continues to improve ~80% of women diagnosed with breast cancer will be survivors This is a huge and increasing population How do we best serve the almost 3 million survivors?
3 Understanding Appropriate Follow-up is Important Overuse of medical resources for follow-up appears common in long-term survivors (Hensley et al, BCRT; 2005) Follow-up should be performed to detect problems that can be treated with curative intent, or controlled for long duration
4 What are the Goals of Follow-up Care? Monitor and treat symptoms Related to completed and ongoing treatment Related to disease diagnosis Psychosocial Fertility Diagnosis of recurrence New primary cancers Screen for genetic risk Locoregional recurrence Distant metastases Facilitate reporting of symptoms
5 Who Should be Referred for Genetic Counseling? Age < 50 at diagnosis; TNBC age < 60 History of bilateral breast cancer Ashkenazi Jewish heritage, age < 50 History of ovarian cancer Family history of: First or second degree relative with bilateral breast cancer First degree relative with breast cancer < age 50 First or second degree relative with ovarian cancer Male relative with breast cancer Adapted from NCCN and PSTF guidelines
6 Screening for New Cancers Mammography Lack of high level evidence to support an impact on DFS or OS (Grunfeld et al, Breast,2002;11:228, Esserman and Thompson, JAMA 2009) Ongoing controversy: mammography is best at detecting low risk disease Observational studies suggest that the method of detection does not influence survival Decreased specificity and sensitivity in the irradiated breast 62% of women in one series did not have a follow-up mammogram in the first year following diagnosis (Mandelblatt et al JCO,2006;24:77)
7 Recommendations Mammography First post treatment within first year (no earlier than 6 months after RT), then yearly if stable Breast self-exam Monthly Clinical breast exam Every 3-6 months for the first 3 years Every 6-12 months for the next 2 years Then annually MRI Decision should be based on an individual basis considering: Genetic risk factors Young age, dense breasts Mammographically occult tumors Khatcheressian JL, et al, JCO 31:961-5, 2013
8 Relative Risk of CL BC Based on Familial Risk: Swedish Registry Parameter N RR (95% CI) Reference rate All women, no FH or CL BC 90, Familial risk, all women 7, ( ) Familial risk, no CL BC 6, ( ) Risk for CL breast, all women 5, ( ) Risk for CL breast, no family history 4, ( ) Risk for CL breast, with family history ( ) NOTE: Data were adjusted for age, parity, and age at first birth. Boldface indicates that RR was statistically >1.00 (Hemminki et al, 2007 Cancer Res;67:868)
9 Detection of Locoregional Recurrences Meta-analysis of 12 studies 378 isolated LRR in 5,045 patients (7.5%) 58% diagnosed during routine visits or with routine tests 40% had no symptoms No data on survival or QOL Based on type of surgery 158/1,948 (8%) with mastectomy 47% (75) asymptomatic at routine FU 152/1,648 (9%) with breast conservation 36% (54) asymptomatic at routine FU de Bock et al; JCO 22:4010, 2004
10 What is the Role of Follow-up in Detecting Local Recurrence? Netherlands Cancer Registry random sampling in first 5 years of FU Studied mode of relapse FU with multiple medical disciplines increased the number of visits 9 recommended 14 and 18 visits for 2 and 3 disciplines To detect one locoregional recurrence or second primary breast cancer 1,349 PEs vs 262 mammograms and/or MRI tests Imaging is important, PEs are not Geurts et al, BCRT 2012
11 Detection of Early Recurrences Hypotheses: 1. Aggressive follow-up detects recurrences at an earlier stage 2. Early treatment of recurrences offers a better chance of cure, longer survival or improvement in QOL. However, data suggest that this is not the case
12 Detection of Early Recurrences Justifications: Early detection results in more effective treatment Patients are reassured does this improve quality of life? Investigational endpoint Monitor effectiveness of adjuvant therapy Disadvantages: Aggressive screening results in overtreatment of early disease Routine testing creates anxiety and need for additional tests Increased costs to patients without benefit
13 What is the Value of Intensive Diagnostic Followup? GIVIO study, JAMA 1994:271; Italian sites 1320 women < 70 yo, stage I-III breast cancer Treatment defined by nodal status Randomization Intensive follow-up with PE and LFTs (q 3m x 8 then q 6m), CXR (q 6m x 4), bone scan and liver US (q 12m) Control PE (q 3 m x 8 then q 6m), additional tests dictated by symptoms Both had annual mammograms Primary endpoints Overall survival Health Related quality of life
14 GIVIO Trial: Results Impact of Follow-up Testing 71 mo F/U Deaths (%) Med.Time to Met (mo) Intensive 132 (20) Control 122 (18) Distant mets Asymptomatic in 31% intensive, 21% control 69-79% presented with symptoms No difference in: Overall survival Quality of life
15 What is the Value of Intensive Diagnostic Followup (2)? Roselli Del Turco, JAMA 1994;271: women from 12 Italian sites Randomized: Intensive: MD visit, mammogram, CXR, bone scan q 6 mo Control: MD visit, mammogram Primary endpoint 5 year survival Results More thoracic and bone mets detected in intensive arm (112 v 70), no impact on survival #Distant Recurrences (%) Mortality (%) Intensive 164 (26.4) 18.6 Control 125 (20.1) 19.5
16 Primary Care vs Oncologist Observed for 4.5 yrs after diagnosis Primary endpoint: Recurrence-Related Serious Clinical Events (SCEs) Secondary endpoint: health-related QOL Family Practice Cancer Center Recurrences 54 (11.2%) 64 (13.2%) Deaths 29 (6.1%) 30 (6.2%) SCEs 17 (3.5%) 18 (3.7%) No difference in health-related QOL Grunfeld E et al. JCO 2006, JCO 2011
17 What is the Role of Tumor Associated Antigens? CEA, CA 15-3, CA Elevated in 30 65% of distant recurrences with lead time of about 4-6 months Measured every 2-3 months: Chan DW, JCO 1997
18 The Case Against! Patient outcomes are not improved by routine measurement of tumor antigens to detect early recurrence Average 5-month lead-time in diagnosis does not change treatment or outcome At least 2 clinical guideline expert panels independently recommend against routine monitoring Additional expense, reimbursement may be a challenge in some settings Generates patient anxiety and need for additional follow-up and testing
19 Consensus Recommendations for Follow-up Annual mammography (at least 6 months after breast radiation Other routine cancer screening Regular clinic visits for H and P Every 3-6 months for 3 years, every 6 months for 2 years, then yearly Health care maintenance Bone and cardiovascular health No routine testing (labs, tumor markers or imaging). Testing as indicated by clinical findings. Resources: NCCN.org ASCO guidelines, 2012 (ASCO.org/guidelines/breastfollowup) American Cancer Society
20 Monitoring and Treatment Symptom Hot flashes Sexual dysfunction (libido, dyspareunia) Weight gain Depression, fatigue Cognitive dysfunction Osteopenia/porosis Cardiovascular disease Thrombosis Secondary malignancies Management options SSRIs, SSNRIs, gabapentin Vaginal moisturizer, vaginal estrogen (on tamoxifen) or introitus Exercise (Daley et al, JCO 2007;25:1713), Diet Counseling, treat underlying cause, time Tools for improving function Calcium/vit D, weight bearing exercise, anti-osteoclast agents Monitor lipid panel, evaluate symptoms Family and personal history Screening, evaluate symptoms Hayes, NEJM 2007;356:2505
21 USPSTF Draft Recommendations 2013 National Lung Screening Trial 53, 454 patients at high risk for lung cancer At least 30 pack/years, age Three annual screenings with: Low dose CT or CXR Results High adherence (>90%) Rate of positive tests CT: 24.2% CXR: 6.9% False positives in 96% (CT) and 95% (CXR) Screening with CT resulted in a 20% relative reduction in mortality Annual low-dose chest CT screening recommended ages with at least 30 pack-years current or former smoker (within 15 years)
22 CIRCULATING TUMOR CELLS Transition state to metastasis? Minimal residual disease Accessible tumor cells for biomarker development Danila D C et al. Clin Cancer Res 2011;17:
23 Pooled Analysis of Prognostic Impact of Disseminated Tumor Cells in Bone Marrow: 10 yr Survival of 4703 Breast Cancer Patients Pooled analysis from 9 centers Prevalence of disseminated tumor cells (DTC) in bone marrow (BM) Breast Cancer Stage I-III Pts. No OMC in BM 3,265 (69%) OMC in BM 1,438 (31%) Braun et al, Cancer Investig 2009
24 Subgroups Cancer-specific survival Chemotherapy only 1,596 patients DTC-Prevalence 38% MR 2.34 (95%CI; ); p<0.001 Endocrine Treatment only 1,499 patients DTC-Prevalence 30% MR 2.05 (95%CI; ); p<0.001 T1N0, no systemic adjuvant treatment 1,499 patients DTC-Prevalence 38% MR 1.61 (95%CI; ); p=0.001 Prognotic value independent of tumor size, grading, receptor status with HR 3.83 (95% CI )
25 Conclusions DTC are a strong prognosticator for all endpoints Indicate early and multiple distant mets Strong prognosticator in all subgroups Value in T1N0 suggests role in cancer progression Consider DTC as a stratification factor in clinical trials? As a surrogate marker of therapeutic efficacy? What is the role of DTC in breast cancer progression? Most patients with CTC did not display overt metastasis Need predictors of behavior of DTCs Ongoing trials Denosumab (anti-rank ligand antibody)
26 Promoting a Healthy Lifestyle in Cancer Survivors: ACS Guidelines for Cancer Prevention Be as lean as possible throughout life (without being underweight). Balance caloric intake with physical activity. Avoid excessive weight gain throughout the lifecycle. Achieve and maintain a healthy weight if currently overweight or obese. Adopt a physically active lifestyle. Adults: at least 30 minutes of moderate-to-vigorous physical activity, on 5 or more days of the week minutes of intentional physical activity preferable. Consume a healthy diet, with an emphasis on plant sources. Choose foods and beverages in amounts that help achieve and maintain a healthy weight. Eat five or more servings of a variety of vegetables and fruits each day, choose whole grains in preference to processed Limit consumption of processed and red meats. If you drink alcoholic beverages, limit consumption. Drink no more than one drink per day for women or two per day for men.
27 Give all patients ASCO follow-up guidelines and document it! Cancer.net Discuss diet and exercise
28 Summary Follow-up for women with a history of early stage breast cancer should include breast imaging and periodic H/P Early follow-up important role for medical and psychologic reasons and to facilitate adherence Frequency of visits should be minimized Early detection of second primary cancers and perhaps LRR is beneficial Frequency of visits should be individualized Duplication should be avoided
29 Summary (2) Routine laboratory and imaging studies have not changed survival Very early detection of occult disease, new therapies could possibly change our approach Individualize approach in very high risk patients Cost effective follow-up strategies need to be developed and implemented Computerized input of symptom data with telephone follow-up Routine follow-up with nurse practioner/physician assistants Identification of patients at risk, and early intervention of high risk groups, is currently being studied
Cancer Survivorship: What to Monitor and When to Intervene. Hyman B. Muss, MD 31 th Miami Breast Cancer Conference 2014
Cancer Survivorship: What to Monitor and When to Intervene Hyman B. Muss, MD 31 th Miami Breast Cancer Conference 2014 Breast Cancer 2013 Incidence Mortality CA: A Cancer Journal for Clinicians pages 52-62,
More informationEarly Stage Breast Cancer Survivorship
Early Stage Breast Cancer Survivorship Jennifer R. Klemp, PhD, MPH, MA Associate Professor of Medicine, Division of Clinical Oncology Director, Cancer Survivorship Cancer Risk and Genetic Counseling University
More informationScreening and Detection in Cancer Survivors. Jose W. Avitia, MD Oncology/Hematology
Screening and Detection in Cancer Survivors Jose W. Avitia, MD Oncology/Hematology Breast Cancer Summary of 2012 ASCO guideline recommendations for surveillance after breast cancer treatment History/physical
More informationFollow-up Care of Breast Cancer Patients
Follow-up Care of Breast Cancer Patients Dr. Simon D. Baxter, MD, FRCPC Medical Oncologist BC Cancer Kelowna Clinical Instructor, Dept of Medicine University of British Columbia 24 November 2018 Disclosures
More informationFollow-up Care of Breast Cancer Patients
Follow-up Care of Breast Cancer Patients Dr. Simon D. Baxter, MD, FRCPC Medical Oncologist BC Cancer Kelowna Clinical Instructor, Dept of Medicine University of British Columbia 19 April 2018 Disclosures
More informationCase 1. BREAST CANCER From Diagnosis to Treatment: The Role of Primary Care
BREAST CANCER From Diagnosis to Treatment: The Role of Primary Care Leah Karliner, MD MAS University of California San Francisco Primary Care Medicine Update 2009 April 2009 Case 1 AR, a 60 year old African
More informationSurgical treatment of BRCA mutated patients. Viviana Galimberti MD European Institute of Oncology Milan, Italy
Surgical treatment of BRCA mutated patients Viviana Galimberti MD European Institute of Oncology Milan, Italy No pharmaceutical company funding was used I declare I have no conflicts of interest as regards
More informationBreast Cancer: Selected Topics for the Primary Care Clinician
Breast Cancer: Selected Topics for the Primary Care Clinician Leah Karliner, MD MAS October 2009 Primary Care Medicine: Principles and Practice OUTLINE Incidence and Mortality Risk Factors and Risk Reduction/Prevention
More informationBreast Cancer Survivorship
Breast Cancer Survivorship Melissa Accordino, MD Assistant Professor of Medicine Herbert Irving Comprehensive Cancer Center Columbia University Medical Center Who are the Cancer Survivors? More than 1
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More informationCaring for a Patient with Colorectal Cancer. Objectives. Poll question. UNC Cancer Network Presented on 10/15/18. For Educational Use Only 1
Caring for a Patient with Colorectal Cancer Tammy Triglianos RN, APRN-BC, AOCNP Nurse Practitioner, GI Oncology 10/15/2018 Objectives Describe common signs and symptoms of colorectal cancer Understand
More informationLong Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer
Global Breast Cancer Conference 2017 21 st Apr, 2017@Chezu Island Long Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer Shinji Ohno, M.D., Ph.D., F.A.C.S. Breast
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationLung Cancer Screening: To screen or not to screen?
Lung Cancer Screening: To screen or not to screen? Dan J. Raz, M.D. Co Director, Lung Cancer Screening Program Co Director, LungCancer and Thoracic OncologyProgram Assistant Professor, Thoracic Surgery
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationCaring for Survivors. Nancy Houlihan, RN, MA, AOCN. Cancer Survivorship Program
Caring for Survivors Nancy Houlihan, RN, MA, AOCN Cancer Survivorship Program Survivors Growing numbers of survivors Convergance of ageing population and numbers surviving cancer Greatest number are over
More informationCancer Prevention & Control in Adolescent & Young Adult Survivors
+ Cancer Prevention & Control in Adolescent & Young Adult Survivors NCPF Workshop July 15-16, 2013 Patricia A. Ganz, MD UCLA Schools of Medicine & Public Health Jonsson Comprehensive Cancer Center + Overview
More informationUpdates In Cancer Screening: Navigating a Changing Landscape
Updates In Cancer Screening: Navigating a Changing Landscape Niharika Dixit, MD I have no conflict of interest. 1 Why Should You Care Trends in Cancer Incidence by Site United States. Siegal Et al: CA
More informationKaren Syrjala, PhD Co-Director, Survivorship Program
Karen Syrjala, PhD Co-Director, Survivorship Program 1. Who are survivors of cancer? 2. Why do you care about your needs as a survivor? 3. What can you do to stay well as a survivor? Who are Survivors?
More informationMastectomy For Treatment, For Prevention, For Prophylaxis Not as Simple as Following Data
Mastectomy For Treatment, For Prevention, For Prophylaxis Not as Simple as Following Data Nathalie Johnson, MD FACS Medical Director, Legacy Cancer Institute and Breast Health Centers Objectives Understand
More information2017 Breast Cancer Update
2017 Breast Cancer Update Alberto J Montero, M.D., MBA Quality Improvement Officer, Taussig Cancer Institute, Lerner College of Medicine Cleveland Clinic N/A Disclosure Overview Epidemiology (US/Global)
More informationPage 1. Selected Controversies. Cancer Screening! Selected Controversies. Breast Cancer Screening. ! Using Best Evidence to Guide Practice!
Cancer Screening!! Using Best Evidence to Guide Practice! Judith M.E. Walsh, MD, MPH! Division of General Internal Medicine! Womenʼs Health Center of Excellence University of California, San Francisco!
More informationIdentifying and Meeting the Medical and Psychological Needs of Cancer Survivors Ann H. Partridge, MD, MPH
Identifying and Meeting the Medical and Psychological Needs of Cancer Survivors Ann H. Partridge, MD, MPH 2017 Master Class Course Presenter Disclosure Information The following relationships exist related
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationSelected Controversies. Cancer Screening. Breast Cancer Screening. Selected Controversies. Page 1. Using Best Evidence to Guide Practice
Cancer Screening Using Best Evidence to Guide Practice Judith M.E. Walsh, MD, MH Division of General Internal Medicine Women s Health Center of Excellence University of California, San Francisco Selected
More informationBreast Cancer Update Michael B. Peyser MS MD FACS Fellow Society of Surgical Oncology Windsong Breast Care
Breast Cancer Update 2017 Michael B. Peyser MS MD FACS Fellow Society of Surgical Oncology Windsong Breast Care Used with permission by Anna Chen MD, Windsong Radiology Group Statistics as of 2013 230,815
More information38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %
38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype
More informationPCORI and PCOR. David R. Flum, MD MPH
PCORI and PCOR David R. Flum, MD MPH Questions to Address PCOR vscer? PCORI update Creation story What it's looking for in topics Stakeholder engagement Approach w methods report D&I and open science policy
More informationEstablishing a Survivorship Program Within a Large Academic Medical Center
Establishing a Survivorship Program Within a Large Academic Medical Center Andrew J. Ward FNP-BC Surgical Oncology, The University of Tennessee Medical Center Disclosures I have no disclosures. Program
More informationSurvivorship After Allogeneic Stem Cell Transplantation: Monitoring, Management and Quality of Life
1 Survivorship After Allogeneic Stem Cell Transplantation: Monitoring, Management and Quality of Life Stephanie J. Lee, MD, MPH Fred Hutchinson Cancer Research Center April 16, 2016 (40 min) Hematopoietic
More informationThe Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer
The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer Laura Spring, MD Breast Medical Oncology Massachusetts General Hospital Primary Mentor: Dr. Aditya Bardia
More informationImaging Surveillance in Women with a History of Treated Breast Cancer. Wei Tse Yang, M.D.
Imaging Surveillance in Women with a History of Treated Breast Cancer Wei Tse Yang, M.D. Breast Cancer 1. Extent 2. Response 3. Recurrence Surveillance Breast Cancer 1. Extent 2. Response Surveillance
More informationSurvivorship in Cancer Care. Samantha Gray Medical Oncologist, SJRH April 20, 2018
+ Survivorship in Cancer Care Samantha Gray Medical Oncologist, SJRH April 20, 2018 + Disclaimers n Participated in Advisory Boards for Amgen, Astellas, Bayer, Janssen, Novartis, Pfizer, Sanofi n Have
More informationCurrent Strategies in the Detection of Breast Cancer. Karla Kerlikowske, M.D. Professor of Medicine & Epidemiology and Biostatistics, UCSF
Current Strategies in the Detection of Breast Cancer Karla Kerlikowske, M.D. Professor of Medicine & Epidemiology and Biostatistics, UCSF Outline ν Screening Film Mammography ν Film ν Digital ν Screening
More informationASCO Publishes "Top Five" List of Opportunities to Improve Quality and Value in Cancer Care
Published on ASCO (https://www.asco.org) Home > ASCO Publishes "Top Five" List of Opportunities to Improve Quality and Value in Cancer Care ASCO Publishes "Top Five" List of Opportunities to Improve Quality
More informationInes Buccimazza 16 TH UP CONTROVERSIES AND PROBLEMS IN SURGERY SYMPOSIUM
BILATERAL MASTECTOMY IS NOT ROUTINELY JUSTIFIED IN PATIENTS WITH BILATERAL AXILLARY LYMPHADENOPATHY AND ONLY ONE DETECTABLE PRIMARY BREAST CANCER LESION SURGERY SYMPOSIUM Ines Buccimazza Breast Unit Department
More informationBeth Goings, RN, NP. Cancer Survivorship, Preventative Care and Screening. Sacred Encounters Perfect Care Healthiest Communities
Beth Goings, RN, NP Cancer Survivorship, Preventative Care and Screening Sacred Encounters Perfect Care Healthiest Communities What is Survivorship An individual is considered a survivor since the time
More informationSurveillance Guidelines Section 1. Surveillance Imaging Section 2. Lymphedema Section 3. Fatigue / Dyspnea Section 4. Weight Gain Section 5
Surveillance Guidelines Section 1 Surveillance Imaging Section 2 Lymphedema Section 3 Fatigue / Dyspnea Section 4 Weight Gain Section 5 Menopausal Symptoms Section 6 Peripheral Neuropathy / Arthralgia
More informationPrinciples of breast radiation therapy
ANZ 1601/BIG 16-02 EXPERT ESMO Preceptorship Program 2017 Principles of breast radiation therapy Boon H Chua Professor Director of Cancer and Haematology Services UNSW Sydney and Prince of Wales Hospital
More informationORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationPhysician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer
Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Gabriela M. Vargas, MD Kristin M. Sheffield, PhD, Abhishek Parmar, MD, Yimei Han, MS, Kimberly M. Brown,
More informationA Model of Shared-Care of the Cancer Survivor. Mary S. McCabe
A Model of Shared-Care of the Cancer Survivor Mary S. McCabe Survivorship Care: An International Endeavor Cancer Survivors Risks of Health Outcomes Comorbidities Lifestyle Behaviors Exposures Surgery Chemotherapy
More informationRole of Prophylactic Cranial Irradiation in Small Cell Lung Cancer
Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Kazi S. Manir MD,DNB,ECMO,PDCR Clinical Tutor Department of Radiotherapy R. G. Kar Medical College and Hospital, Kolkata SCLC 15% of lung
More informationIOM Workshop: Achieving Value in Cancer Care: ASCO s Top 5 and Beyond Lowell E. Schnipper, M.D.
IOM Workshop: Achieving Value in Cancer Care: ASCO s Top 5 and Beyond Lowell E. Schnipper, M.D. Expenditures Cancer Care: 2010 Initial dx, continuing care, last phase Costs of Cancer Care: breast, colorectal,
More informationPaul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia
Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Virginia - Chesapeake Bay Landfall: Virginia Beach, April 29 th, 1607 PSA Failure after Radical Prostatectomy
More informationWork-up/Follow-up: Baseline and Surveillance Studies for Cutaneous Melanoma Patients
2018 AAD Annual Meeting, San Diego, CA Work-up/Follow-up: Baseline and Surveillance Studies for Cutaneous Melanoma Patients Susan M. Swetter, MD, FAAD Professor of Dermatology Director, Pigmented Lesion
More informationExamine breast cancer trends, statistics, and death rates, and impact of screenings. Discuss benefits and risks of screening
Define Breast Cancer Screening Examine breast cancer trends, statistics, and death rates, and impact of screenings Discuss benefits and risks of screening Compare and contrast Screening Guidelines Optimal
More informationBreast Cancer Screening and High Risk
Breast Cancer Screening and High Risk Mary Freyvogel, DO Breast Surgeon Clinical Assistant Professor of Surgery University Hospitals Case Medical Center St. John Medical Center / Elyria Medical Center
More informationSpeaker s Bureau. Travel expenses. Advisory Boards. Stock. Genentech Invuity Medtronic Pacira. Faxitron. Dune TransMed7 Genomic Health.
Management of DCIS Shawna C. Willey, MD, FACS Professor of Surgery, Georgetown University Director, Medstar Regional Breast Health Program Chief, Department of Surgery Medstar Georgetown University Hospital
More informationEvolution of Regional Nodal Management of Breast Cancer
Evolution of Regional Nodal Management of Breast Cancer Bruce G. Haffty, MD Director (Interim) Rutgers Cancer Institute of New Jersey Professor and Chair Department of Radiation Oncology Rutgers, The State
More informationWhen do you need PET/CT or MRI in early breast cancer?
When do you need PET/CT or MRI in early breast cancer? Elizabeth A. Morris MD FACR Chief, Breast Imaging Service Memorial Sloan-Kettering Cancer Center NY, NY Objectives What is the role of MRI in initial
More informationNutrition and Cancer. Prof. Suhad Bahijri
Nutrition and Cancer Objectives 1. Discuss current knowledge regarding nutritional prevention of cancer 2. Discuss goals for the cancer patient 3. Explain how cancer treatment affects nutritional needs
More informationWhy Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA Why Do Axillary Dissection? 6 August 2011 Implications
More informationIntensive follow up after primary. PRO: Pierfranco Conte
Intensive follow up after primary curative therapy PRO: Pierfranco Conte Follow up : Guidelines Mammography PE BSE Intensive Follow-up BMD (DEXA) Gynecologic examination AIOM 1 (2012) yearly Q 3/6 m for
More informationCase Conference: Post-Mastectomy Radiotherapy
Case Conference: Post-Mastectomy Radiotherapy Outline - Case Intro Guidelines Studies - Case Conclusion Summary Outline Case Intro to PMRT Guidelines Studies Case conclusion Summary Outline - Case Intro
More informationNutrition and Cancer Prevention. Elisa V. Bandera, MD, PhD
Nutrition and Cancer Prevention Elisa V. Bandera, MD, PhD The Causes of Cancer in the US. Sedentary lifestyle 5% Other 12% Family history 5 % Occupation 5% Tobacco 30% Reproductive factors 3% Pollution
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
:$;7)#*8'-87*4BCD'E7)F'31$4.$&'G$H'E7)F&'GE'>??ID >?,"'@4,$)4*,#74*8'!74/)$++'74',"$'A.,.)$'7%'()$*+,'!*42$)!7)74*67&'!3 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationUpdate in Breast Cancer Screening
Disclosure information: Update in Breast Cancer Screening Karla Kerlikowske, MDDis Update in Breast Cancer Screening Grant/Research support from: National Cancer Institute and Grail - and - Karla Kerlikowske,
More informationCancer Screening I have no conflicts of interest. Principles of screening. Cancer in the World Page 1. Letting Evidence Be Our Guide
Cancer Screening 2012 Letting Evidence Be Our Guide Jeffrey A. Tice, MD Division of General Internal Medicine University of California, San Francisco I have no conflicts of interest Principles of screening
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationFollow-up in breast cancer patients: intensive vs minimal, centralized vs distributed. Alessandra Huscher
Follow-up in breast cancer patients: intensive vs minimal, centralized vs distributed Alessandra Huscher Follow-up in breast cancer patients: facts and myths What is exactly follow-up? an action or thing
More informationThe Role of Sentinel Lymph Node Biopsy and Axillary Dissection
The Role of Sentinel Lymph Node Biopsy and Axillary Dissection Henry Mark Kuerer, MD, PhD, FACS Department of Surgical Oncology University of Texas MD Anderson Cancer Center SLN Biopsy Revolutionized surgical
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationChemo-endocrine prevention of breast cancer
Chemo-endocrine prevention of breast cancer Andrea DeCensi, MD Division of Medical Oncology Ospedali Galliera, Genova; Division of Cancer Prevention and Genetics, European Institute of Oncology, Milano;
More informationPost-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)
Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and Women s Hospital Harvard Medical School Conclusions When considering PMRT, use both
More informationBreast Cancer Risk Assessment and Prevention
Breast Cancer Risk Assessment and Prevention Katherine B. Lee, MD, FACP October 4, 2017 STATISTICS More than 252,000 cases of breast cancer will be diagnosed this year alone. About 40,000 women will die
More informationBy: Tania Cortas, MD Arizona Oncology 03/10/2015
By: Tania Cortas, MD Arizona Oncology 03/10/2015 Epidemiology In the United States, CRC incidence rates have declined about 2 to 3 percent per year over the last 15 years Death rates from CRC have declined
More informationPublished Ahead of Print on October 10, 2006 as /JCO J Clin Oncol by American Society of Clinical Oncology INTRODUCTION
Published Ahead of Print on October 10, 2006 as 10.1200/JCO.2006.08.8575 The latest version is at http://www.jco.org/cgi/doi/10.1200/jco.2006.08.8575 VOLUME 24 NUMBER 31 NOVEMBER 1 2006 JOURNAL OF CLINICAL
More informationIncreased Risk of Breast Cancer: Screening and Prevention. Elizabeth Pritchard, MD 4/5/2017
Increased Risk of Breast Cancer: Screening and Prevention Elizabeth Pritchard, MD 4/5/2017 No disclosures Defining Risk Risk Factors Modifiable Lifestyle obesity physical activity alcohol consumption breast
More informationDisclosures. Overview. Selection the most accurate statement: Updates in Lung Cancer Screening 5/26/17. No Financial Disclosures
Updates in Lung Cancer Screening Disclosures No Financial Disclosures Neil Trivedi, MD Associate Professor of Clinical Medicine SF VAMC Pulmonary and Critical Care Director, Bronchoscopy & Interventional
More informationBREAST DENSITY WHAT IS IT? WHY IS IT IMPORTANT? & What IOWA SF250 Means to Patients and Providers
BREAST DENSITY WHAT IS IT? WHY IS IT IMPORTANT? & What IOWA SF250 Means to Patients and Providers Arnold Honick, MD Radiology Consultants of Iowa, PLC ahonick@rciowa.com BREAST DENSITY LEGISLATION Nancy
More informationHBOC Syndrome A review of BRCA 1/2 testing, Cancer Risk Assessment, Counseling and Beyond.
HBOC Syndrome A review of BRCA 1/2 testing, Cancer Risk Assessment, Counseling and Beyond. Conni Murphy, ARNP Cancer Risk Assessment and Genetics Program Jupiter Medical Center Learning Objectives Identify
More informationSo, Who are the appropriate individuals that should consider genetic counseling and genetic testing?
Hello, I m Banu Arun, Professor of Breast Medical Oncology and Co-Director of Clinical Cancer Genetics at the University of Texas MD Anderson Cancer Center. Today I will be discussing with you Hereditary
More informationRadiotherapy Implications of ACOSOG Z-11 for Clinical Practice. Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin
1 Radiotherapy Implications of ACOSOG Z-11 for Clinical Practice Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin Disclosures: none Agenda 1. ACOSOG Z-11: Another perspective
More informationBreast Cancer: Current Approaches to Diagnosis and Treatment
Breast Cancer: Current Approaches to Diagnosis and Treatment Barbara L. Smith, MD, Ph.D. Massachusetts General Hospital Division of Surgical Oncology No Disclosures Incidence of Breast Cancer USA 2018
More informationRole of Cancer Registries and Data Banking in Quality Control of Breast Cancer Care
4 th International Congress of Breast Role of Cancer Registries and Data Banking in Quality Control of Breast Cancer Care Adri C. Voogd, PhD, epidemiologist Department of Epidemiology, Maastricht University
More informationThoracic Recurrences. Soft tissue recurrence
Stereotactic body radiotherapy for thoracic and soft malignancies Alexander Gottschalk, M.D., Ph.D. Associate Professor Director of CyberKnife Radiosurgery Department of Radiation Oncology University of
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationUnique Aspects of Breast Cancer in African American Women: TRIPLE NEGATIVE BREAST CANCER
Angel A. Rodriguez, M.D. Assistant Professor Weill Cornell Medical College Methodist Cancer Center January 26, 2013 Unique Aspects of Breast Cancer in African American Women: TRIPLE NEGATIVE BREAST CANCER
More informationEarly Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10
More informationPMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
More informationNSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions
1 1 NSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health
More information03/14/2019. Postmastectomy radiotherapy; the meta-analyses, and the paradigm change to altered fractionation Mark Trombetta M.D.
radiotherapy; the meta-analyses, and the paradigm change to altered fractionation Mark Trombetta M.D. Division of Radiation Oncology Allegheny Health Network Cancer Institute Professor of Radiation Oncology
More informationBreast Cancer Screening and Treatment Mrs Belinda Scott Breast Surgeon Breast Associates Auckland
Breast Cancer Screening and Treatment 2009 Mrs Belinda Scott Breast Surgeon Breast Associates Auckland BREAST CANCER THE PROBLEM 1.1 million women per year 410,000 deaths each year Increasing incidence
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationRadiotherapy symptoms control in bone mets. Francesco Cellini GemelliART. Ernesto Maranzano,MD. Session 5: Symptoms management
Session 5: Symptoms management Radiotherapy symptoms control in bone mets Francesco Cellini GemelliART Ernesto Maranzano,MD Director of Oncology Department Chief of Radiation Oncology Centre S. Maria Hospital
More informationHEALTH CARE DISPARITIES. Bhuvana Ramaswamy MD MRCP The Ohio State University Comprehensive Cancer Center
HEALTH CARE DISPARITIES Bhuvana Ramaswamy MD MRCP The Ohio State University Comprehensive Cancer Center Goals Understand the epidemiology of breast cancer Understand the broad management of breast cancer
More informationOutline. WBRT field. Brain Metastases. Whole Brain RT Prophylactic WBRT Stereotactic radiosurgery (SRS) 1 fraction Stereotactic frame
Radiation Therapy for Advanced NSC Lung Ca Alexander Gottschalk, M.D., Ph.D. Associate Professor Director of CyberKnife Radiosurgery Department of Radiation Oncology University of California San Francisco
More informationHow can we Personalize RT as part of Breast-Conserving Therapy?
How can we Personalize RT as part of Breast-Conserving Therapy? Jay R. Harris Dana-Farber Cancer Institute (DFCI) Brigham and Women s Hospital (BWH) Harvard Medical School Disclosures I have no COI disclosures
More informationBreast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More information4/13/2010. Silverman, Buchanan Breast, 2003
Tailoring Breast Cancer Treatment: Has Personalized Medicine Arrived? Judith Luce, M.D. San Francisco General Hospital Avon Comprehensive Breast Care Center Outline First, treatment of DCIS Sorting risk
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationRisk Assessment, Genetics, and Prevention
Risk Assessment, Genetics, and Prevention Katherine D. Crew, MD MS Director, Clinical Breast Cancer Prevention Program Columbia University Medical Center 1 Outline Breast cancer risk factors Hereditary
More informationThe Cambridge Breast Unit
The Addenbrooke s Hospital Cambridge Cambridge Follow up- Why?- Medical Monitor and treat Acute side effects of treatment Early detection of Local and Regional Recurrences (Curative) Early detection of
More information